Abstract:Objective: Lung cancer is one of the leading causes of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. With the emergence of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), the prognosis of adenocarcinoma patients with specific EGFR mutations has been significantly improved. Unfortunately, despite the success of EGFR-TKIs in NSCLC patients, almost all cases eventually recrudesce after a median of 10 months. Therapeutic antibodies blocking programmed death-ligand 1 (PD-L1) brought striking regression of NSCLC. However, only 20% patients response to the αPD-L1 therapy. Activation of EGFR signaling pathway was also reported to induce PD-L1 expression in NSCLC. MUC3A is a transmembrane mucin with 2 epidermal growth factor (EGF)-like domains in the extracellular segment. This work aimed to investigate the effects of MUC3A on PD-L1 expression and EGFR-TKIs sensitivity in EFGR-mutant NSCLC. Methods: Expression levels of MUC3A and PD-L1 in tissue microarray of 92 patients9 lung tumor samples were measured by immunohistochemistry. Data of lung cancer were downloaded from the TCGA database, and the correlation of PD-L1 expression between EGFR wild type and mutation in lung cancer patients was analyzed. H1975 and PC-9 cells were infected with lentiviral vectors to downregulate MUC3A. The expression pattern of PD-L1 in NSCLC cell lines was detected by qRT-PCR and flow cytometry. Cell proliferation was assessed with CCK-8. Cell apoptosis was examined by flow cytometry. Immunoblotting was used to identify molecular markers of signaling pathways. An xenograft nude mouse transplantation model was established to examine the effects of MUC3A and EGFR-TKIs on tumorigenesis in vivo. The expression levels of MUC3A, EGFR and PD-L1 in harvested tumors were measured by immunohistochemistry. Results: Tissue microarray of 92 patients9 lung tumor samples indicated that high levels of MUC3A were positively correlated with poor prognosis and PD-L1 expression. In the TCGA database, the levels of PD-L1 were independent of the protein levels of EGFR, but correlated with EGFR mutation. Our results showed that induction of PD-L1 by EGF stimulation was only detected in EGFR-mutated NSCLC cell lines, such as H1975 and PC-9, but not in H1299 and H460. Knockdown of MUC3A in H1975 and PC-9 reduced PD-L1 expression, as well as PI3K/Akt and MAPK pathways. In addition, MUC3A deficiency potentiated gefitinib and AZD-9291-induced growth inhibition in PC-9 and H1975 cells by downregulating proliferation and inducing apoptosis. More interestingly, knockdown of MUC3A decreased EGFR protein levels, but not mRNA levels. Our findings suggested that MUC3A deficiency improved EGFR-mutated NSCLC sensitivity to tyrosine kinase inhibitors via increasing EGFR protein stability and decreasing PD-L1 expression through PI3K/Akt and MAPK pathways. Mice inoculated with MUC3A deficiency tumor cells treated with AZD-9291 had the fastest tumor regression and delayed relapse. Conclusions: The transmembrane mucin MUC3A increased EGFR stability. MUC3A induced PD-L1 and reduced tyrosine kinase inhibitor effects via EGFR modulation in NSCLC, suggesting potential implications for a novel immunotherapeutic approach. Citation Format: Yuan Luo, Shijing Ma, Yingming Sun, Shan Peng, Yan Gong, Conghua Xie. MUC3A induces PD-L1 and reduces tyrosine kinase inhibitor effects in EGFR-mutant non-small cell lung cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4490.

MUC3A Induces PD-L1 and Reduces Tyrosine Kinase Inhibitors Effects in EGFR-mutant Non-Small Cell Lung Cancer

P1.03-51 MUC3A Induces PD-L1 and Reduces Tyrosine Kinase Inhibitor Effects in EGFR-Mutant Non-Small Cell Lung Cancer

Abstract 4490: MUC3A Induces PD-L1 and Reduces Tyrosine Kinase Inhibitor Effects in EGFR-mutant Non-Small Cell Lung Cancer

Abstract B57: MUC3A Induces PD-L1 and Reduces Tyrosine Kinase Inhibitor Effects Functions in EGFR-mutant Non-Small Cell Lung Cancer

MUC3A Promotes Non-Small Cell Lung Cancer Progress Via Activating NFκB Pathway and Attenuates Radiosensitivity

Abstract 4167: MUC3A Promotes Lung Cancer Progress Via Activating NFκB Pathway and Attenuates Radiosensitivity

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

MUC3A Promotes the Progression of Colorectal Cancer Through the PI3K/Akt/mTOR Pathway.

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

MUC1 Induces Acquired Chemoresistance by Upregulating ABCB1 in EGFR-dependent Manner

T Cell Immunoglobulin and Mucin-Domain Containing-3 in Non-Small Cell Lung Cancer

Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer

MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII

Downregulated Mucin 1 alleviates paclitaxel resistance in non‐small cell lung cancer cells

Association of <i>MUC19</i> Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer

MLL3 Enhances the Transcription of PD-L1 and Regulates Anti-Tumor Immunity.

Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and Its Role in Evaluation of Prognosis

Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer

A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity

Unlocking PD‐1 antibody resistance: The MUC1 DNA vaccine augments CD8+ T cell infiltration and attenuates tumour suppression